New drug combo tested for aggressive bladder and prostate cancers

This early-stage trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy works better for treating advanced small cell or neuroendocrine cancers of the bladder, urethra, or prostate. The study will enroll about 15 participants with cancer that has spread and cannot be cured with surgery alone. Researchers will measure how well the combination shrinks tumors, controls cancer growth, and how safe it is for patients.